Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. Melanotan Ii
2. 121062-08-6
3. Upf5cj93x7
4. Dtxsid90153135
5. L-lysinamide, N-acetyl-l-norleucyl-l-alpha-aspartyl-l-histidyl-d-phenylalanyl-l-arginyl-l-tryptophyl-, Cyclic (2-7)-peptide
6. Refchem:925444
7. Dtxcid3075626
8. Mt-ii
9. Melanotan (mt)-ii
10. Melatonan
11. Melanotan Ii Acetate Salt
12. Chembl430239
13. (3s,6s,9r,12s,15s,23s)-15-[[(2s)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide
14. C50h69n15o9
15. (3s,6s,9r,12s,15s,23s)-12-((1h-imidazol-5-yl)methyl)-3-((1h-indol-3-yl)methyl)-15-((s)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide
16. Mtii
17. Melanotanii
18. Melanotan Ii?
19. Ac-nle-cyclo[asp-his-d-phe-arg-trp-lys]-nh2
20. Unii-upf5cj93x7
21. Melanotan Ii [who-dd]
22. Ebi_340792
23. Gtpl1323
24. Orb1296657
25. Schembl1047531
26. Schembl29473785
27. Chebi:195326
28. Ex-a7394
29. Hy-p0267
30. 121062-08-6 (non-salt)
31. Bdbm50027084
32. Bdbm50184359
33. Mfcd06795842
34. Akos015994654
35. Hs-2017
36. Ncgc00167281-01
37. Da-55328
38. Fa109114
39. F93947
40. 062m086
41. Q423855
42. Acetyl-(nle4,asp5,d-phe7,lys10)-cyclo-alpha-msh (4-10) Amide
43. (3s,6s,9r,12s,15s,23s)-12-((1h-imidazol-5-yl)methyl)-3-((1h-indol-3-yl)methyl)-15-((s)-2-acetamidohexanamido)-9-benzyl-6-(3-((diaminomethylene)amino)propyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide
44. (3s,6s,9r,12s,15s,23s)-15-((s)-2-acetylamino-hexanoylamino)-9-benzyl-6-(3-guanidino-propyl)-12-(3h-imidazol-4-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18hexaaza-cyclotricosane-23-carboxylic Acid Amide
45. (3s,6s,9r,12s,15s,23s)-15-[(n-acetyl-l-norleucyl)amino]-9-benzyl-6-{3-[(diaminomethylidene)amino]propyl}-12-[(1h-imidazol-5-yl)methyl]-3-[(1h-indol-3-yl)methyl]-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide
46. (3s,6s,9r,12s,15s,23s)-15-[[(2s)-2-acetamidohexanoyl]amino]-9-benzyl-6-(3-guanidinopropyl)-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide
47. (3s,6s,9r,12s,15s,23s)-9-benzyl-6-{3-[(diaminomethylidene)amino]propyl}-15-[(2s)-2-acetamidohexanamido]-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide
48. L-lysinamide, N-acetyl-l-norleucyl-l-.alpha.-aspartyl-l-histidyl-d-phenylalanyl-l-arginyl-l-tryptophyl-, Cyclic (2->7)-peptide
| Molecular Weight | 1024.2 g/mol |
|---|---|
| Molecular Formula | C50H69N15O9 |
| XLogP3 | 0 |
| Hydrogen Bond Donor Count | 13 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 17 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 385 |
| Heavy Atom Count | 74 |
| Formal Charge | 0 |
| Complexity | 1950 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
82
PharmaCompass offers a list of Melanotan II API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Melanotan II manufacturer or Melanotan II supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Melanotan II manufacturer or Melanotan II supplier.
A Melanotan II manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Melanotan II, including repackagers and relabelers. The FDA regulates Melanotan II manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Melanotan II API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Melanotan II supplier is an individual or a company that provides Melanotan II active pharmaceutical ingredient (API) or Melanotan II finished formulations upon request. The Melanotan II suppliers may include Melanotan II API manufacturers, exporters, distributors and traders.
click here to find a list of Melanotan II suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Melanotan II as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Melanotan II API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Melanotan II as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Melanotan II and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Melanotan II NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Melanotan II suppliers with NDC on PharmaCompass.
Melanotan II Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Melanotan II GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Melanotan II GMP manufacturer or Melanotan II GMP API supplier for your needs.
A Melanotan II CoA (Certificate of Analysis) is a formal document that attests to Melanotan II's compliance with Melanotan II specifications and serves as a tool for batch-level quality control.
Melanotan II CoA mostly includes findings from lab analyses of a specific batch. For each Melanotan II CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Melanotan II may be tested according to a variety of international standards, such as European Pharmacopoeia (Melanotan II EP), Melanotan II JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Melanotan II USP).